Web
|
Images
|
News
News Home
US
World
Business
Finance
Industry
Technology
Science
Media & Advertising
Politics/Law
Entertainment
Internet
Health
Sports
Culture
Log In
ImClone Reports Favorable Survival Results From BMS-099 Study On ERBITUX In Cancer
Have an interest in this Story?
Sign Up for Real-Time email updates
RTTNews.com
|
August 29, 2008
New York-based biopharmaceutical firm Imclone Systems Inc. (IMCL: News ) Friday reported favorable overall survival results from an open-label, phase-III BMS-099 study of ERBITUX, combined with a taxane and carboplatin, in the first-line treatment of all histological subtypes of advanced non-small c...
Read Full Article
Leave a Comment:
You must be logged in to leave a comment
Log in
|
Register
Most Read World Articles
Holder Seen as Obama Choice for Justice Post
- Amherst Times
Al-Qaida No. 2 insults Obama in new audio message
- Estherville Daily News
Doctors transplant windpipe with stem cells
- Jerusalem Post
Indian navy sinks marauders' mother ship
- Globe and Mail
6:24am Navy destroys pirate 'mother ship'
- The Australian
Featured Members
David Hood
Director
Marketing/Public Relations
Matthew Clark
Mentor
Entrepreneur
View more profiles
Access dozens of premium and subscriptions sites
Free!
Download now
.
Advertise
|
Build a News Circle
|
Get News Briefings
|
Congoo News Home
|
Get the Netpass
About Congoo
|
Terms
|
Privacy
|
Need Help?
|
Site Map
Copyright ©2008 Congoo.com. All Rights Reserved.